Prevention of Relapse of Reflux Esophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with Ranitidine

References

• Tytgat G N J, Nio C Y. The medical therapy of reflux esophagitis. Clin Gastroenterol 1987; 1: 791–807
   Google Scholar
• Koelz H R. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. Analysis of randomized clinical trials. Scand J Gastroenterol 1989; 24(suppl 156)25–36
   Google Scholar
• Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—gastric proton pump inhibitor on pentagastrin-stimulated acid secretion in man. Gut 1983; 24: 270–276
   PubMed Web of Science ®Google Scholar
• Johansson K E, Tibbling L. Maintenance treatment with ranitidine compared with fundoplication in gastroesophageal reflux disease. Scand J Gastroenterol 1986; 21: 779–788
   PubMed Web of Science ®Google Scholar
• Schaub N, Meurick T J, Misiewicz J, Lovell D, Troutman I F. Investigation of ranitidine 150 mg b.i.d. or 300 mg b.i.d. in the treatment of reflux disease. Hepatogastroenterology 1986; 33: 206–213
   PubMedGoogle Scholar
• Ruth M, Ehnbom H, Lundell L, Lönroth H, Sandberg N, Sandmark S. The effect of omeprazole or ranitidine treatment on 24 hour esophageal acidity in patients with reflux esophagitis. Scand J Gastroenterol 1988; 23: 1141–1146
   PubMed Web of Science ®Google Scholar
• Pasqual J C, Hémery P, Bruley S, Galmiche J P. Comparison of the effects of two doses omeprazole on 24-hour esophageal pH in gastroesophageal reflux disease [Abstract]. Gastroenterology 1987; 92: 1567
   Web of Science ®Google Scholar
• Klinkenberg-Knol E C, Jansen J M B J, Festen H P M, Meuwissen S G M, Lamers C B H W. Double blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1987; 1: 349–351
   PubMed Web of Science ®Google Scholar
• Van Trappen G, Rutgeerts L, Shurmans P, Coengrachts J L. Omeprazole (40 mg) is superior to ranitidine in short term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523–529
   PubMed Web of Science ®Google Scholar
• Havelund T, Laursen L S, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in the treatment of reflux esophagitis: double blind comparative trial. Br Med J 1988; 296: 89–92
   PubMed Web of Science ®Google Scholar
• Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double blind, randomized, multicentre study. Scand J Gastroenterol 1988; 23: 625–632
   PubMed Web of Science ®Google Scholar
• Hetzel D J, Dent J, Reed W D, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–912
   PubMed Web of Science ®Google Scholar
• Lundell L, Backman L, Ekström P, et al. Omeprazole or high dose ranitidine in the treatment of patients with reflux esophagitis not responding to standard doses of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145–155
   PubMed Web of Science ®Google Scholar
• Koelz H R, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198–1205
   PubMed Web of Science ®Google Scholar
• Armstrong D, Blum L. Full dose H2-receptor antagonist prophylaxis does not prevent relapse of reflux esophagitis. Gut 1989; 30: 1494A
   Web of Science ®Google Scholar
• Johnson N J, Mills J G, Wood J R. Acute treatment of reflux esophagitis: a multicentre trial comparing ranitidine 150 mg b.i.d. with ranitidine 300 mg q.i.d. Gastroenterology 1989; 96: A242
   Google Scholar
• Skinner D B, Walther B C, Ridell R H, Schmidt H, Lascone C, DeMeester T R. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198: 554–566
   PubMed Web of Science ®Google Scholar
• Grimelius L, Wilander E. Silver staining in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol 1980; 3: 3–12
   PubMedGoogle Scholar
• Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of non-antral gastric endocrine growths in man. Digestion 1988; 41: 145–200
   Web of Science ®Google Scholar
• Pocock S. Clinical trials. Wiley and Sons, Chichester 1983; 221–227
   Google Scholar
• Hetzel D J, Carlsson R, Dent J, Lundell L. Relapse of esophagitis after endoscopic healing, analyses of unfavourable prognostic factors. Gastroenterol Int 1988; 1(suppl 1)A846
   Google Scholar
• Dent J, Klinkenberg-Knol E C, Elm G, Eriksson K, Rikner L, Sölvell L. Omeprazole in the long-term management of patients with reflux esophagitis refractory to histamine H2-receptor antagonist. Gastroenterol Int 1988; 1(suppl 1)A847
   Google Scholar
• Lanzon-Miller S, Pounder R E, Hamilton M R, et al. 24-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239–251
   PubMedGoogle Scholar
• Lind T, Cederberg C, Forssell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastric concentration during omeprazole treatment. Scand J Gastroenterol 1988; 23: 1259–1266
   PubMed Web of Science ®Google Scholar
• Brunner G, Creutzfeldt W, Starky Y, Lamberts R. Therapy with omeprazole in patients with peptical ulcerations resistant to extended high dose ranitidine treatment. Digestion 1988; 39: 80–90
   PubMed Web of Science ®Google Scholar
• Lind T, Cederberg C, Olausson M, Olbe L. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 1990, in press
   PubMedGoogle Scholar
• Lanzon-Miller S, Pounder R E, Hamilton M R, et al. 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal and gastric ulcer or pernicious anaemia. Aliment Pharmacol Ther 1987; 1: 225–237
   PubMedGoogle Scholar
• Walt R B, Gomes M F A, Wood C, Logan L H, Pounder R E. Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 1983; 287: 12–14
   PubMed Web of Science ®Google Scholar
• Axelson J, Håkanson R, Rosengren E, Sundler F. Hypergastrinemia induced by acid blockade evokes enterochromaffin like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissue Res 1988; 254: 511–516
   PubMed Web of Science ®Google Scholar
• Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffin like cells. Activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391–399
   PubMed Web of Science ®Google Scholar
• Borch K, Rehnvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumour in pernicious anemia. Gastroenterology 1985; 88: 638–648
   PubMed Web of Science ®Google Scholar
• Rode J, Dhillon A P, Papadaki L, et al. Pernicious anemia and mucosal endocrine cell proliferation of the non-antral stomach. Gut 1986; 27: 789–798
   PubMed Web of Science ®Google Scholar
• Bordi C, Cocconi G, Togni R, Wezzaolini P, Missale G. Gastric endocrine cell proliferation. Association with Zollinger-Ellison syndrome. Arch Pathol 1974; 98: 274–279
   PubMedGoogle Scholar
• Ekman L, Hansson E, Havu N, Carlsson E, Lundborg P. Toxicological studies on omeprazole. Scand J Gastroenterol 1985; 20(suppl 108)53–69
   Google Scholar
• Simonsson M, Eriksson S, Håkanson R, et al. Endocrine cells in the human oxyntic mucosa. A his-tochemical study. Scand J Gastroenterol 1988; 23: 1089–1099
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion 1988; 39: 61–79
   PubMed Web of Science ®Google Scholar
• Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell population. Digestion 1988; 39: 126–135
   PubMed Web of Science ®Google Scholar